ArticleCancer causes & control : CCC2025
Patterns of care and treatment delays among patients with early-stage breast cancer: long term impact of the COVID-19 (C19) pandemic.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo assess the long-term impact of the COVID-19 (C19) pandemic, we examined treatment patterns and delays in early-stage breast cancer (BC).
methodsPatients ≥ 18 years with clinical stage I-III BC diagnosed between 2019 and 2022 were identified in the National Cancer Database. Patients were categorized as pre-C19 (2019), early-C19 (2020), late-C19 (2021), and post-C19 (2022). Descriptive statistics assessed changes in early-stage BC treatment patterns and time-to-treatment initiation. Multivariable logistic regression was used to identify factors associated with treatment delays > 60 days.
resultsA decline in BC cases was observed during the pre- to early-C19 period, it was more pronounced among patients with stage I disease. While surgery as initial treatment decreased from pre- to post-C19, chemotherapy use increased. The early-C19 period was associated with lower odds of any treatment initiation delays > 60 days (adjusted odds ratio [aOR] = 0.87; 95% CI 0.85-0.89) while late-C19 (aOR = 1.20; 95% CI 1.17-1.22) and post-C19 (aOR = 1.46; 95% CI 1.43-1.49) were associated with higher odds compared to pre-C19. Black (aOR = 1.59; 95% CI 1.55-1.63) and Hispanic (aOR = 1.57; 95% CI 1.53-1.61) patients were more likely to have any treatment initiation delays.
conclusionsThe C19 pandemic disrupted BC care, contributing to ongoing treatment delays. Future studies are needed to understand how systemic factors impact long-term outcomes.
Indexed as
Identifiers
41176513What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.